Cancer – APEC1621SC: The Pediatric MATCH Screening Trial
Condition or Therapy:
non-Hodgkin lymphoma, histiocytic disorders, relapsed or refractory advanced solid tumors
Cancer and Blood Disorders
Study Number: APEC1621SC
What is the goal of this study?
The goal of this phase 2 study is to evaluate patients' overall response rate to treatment.
Who can join the study?
This study may be a good fit for children and young adults who:
- are between the ages of 12 months to 21 years old, and
- have a diagnosis of recurrent or refractory solid tumors, including non-Hodgkin lymphomas; histiocytoses (e.g. langerhans cell histiocytosis [LCH], juvenile xanthogranuloma [JXG], histiocytic sarcoma); or central nervous system (CNS) tumors.
What will happen if my child takes part in this study?
You can read more about this study on clinicaltrials.gov.
Who can I contact for more information?
To learn more, call 206-987-2106 or email the study coordinator.